IDP-023 + rituximab + interleukin-2

This is a combination cellular and immunotherapy regimen comprising **IDP-023** (a g-NK [gamma-minus natural killer] cell therapy developed by Indapta Therapeutics), **rituximab** (an anti-CD20 chimeric monoclonal antibody), and **interleukin-2** (IL-2, a recombinant cytokine that promotes the expansion and activation of NK cells and cytotoxic lymphocytes). - IDP-023 consists of a highly cytotoxic subset of NK cells lacking the FcεR1γ protein, derived from healthy donors exposed to CMV, and is believed to target HLA-E-expressing autoreactive T and B cells, exerting anti-viral and anti-tumor effects primarily through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and direct cytotoxicity[1][3][5]. - Rituximab depletes CD20-positive B cells through ADCC, complement-dependent cytotoxicity, and apoptosis. - Interleukin-2 increases the number and activity of NK and cytotoxic T cells and augments ADCC by stimulating effector immune cells[2][4][6]. The rationale for combining these three agents is to leverage cell-mediated and antibody-mediated immune mechanisms to augment anti-tumor and immunomodulatory activity, particularly in conditions such as progressive multiple sclerosis and hematologic malignancies[3][5][7].